share_log

424B3: Prospectus

424B3: Prospectus

424B3:募資說明書
美股SEC公告 ·  08/19 17:03
Moomoo AI 已提取核心訊息
Conduit Pharmaceuticals Inc. has filed a Form 8-K with the SEC, disclosing non-compliance with Nasdaq's continued listing requirements. Specifically, the company's market value of publicly held shares and market value of listed securities fell below the minimum thresholds. Conduit has 180 days to regain compliance. Additionally, undisclosed dispositions of substantial company shares by a director and a significant stockholder's shares being under third-party pledge were discovered. The board has formed a Special Committee and a Trading Review Committee to investigate and address these issues.
Conduit Pharmaceuticals Inc. has filed a Form 8-K with the SEC, disclosing non-compliance with Nasdaq's continued listing requirements. Specifically, the company's market value of publicly held shares and market value of listed securities fell below the minimum thresholds. Conduit has 180 days to regain compliance. Additionally, undisclosed dispositions of substantial company shares by a director and a significant stockholder's shares being under third-party pledge were discovered. The board has formed a Special Committee and a Trading Review Committee to investigate and address these issues.
Conduit Pharmaceuticals Inc.已向美國證券交易委員會提交了8-K表格,披露未遵守納斯達克持續上市要求,具體來說,公司公開持股市值和上市證券市值均低於最低閾值。 Conduit有180天恢復符合條件。 此外,董事未公開出售大量公司股份,並發現大股東的股份被第三方質押。 董事會已成立特別委員會和交易審查委員會調查和解決這些問題。
Conduit Pharmaceuticals Inc.已向美國證券交易委員會提交了8-K表格,披露未遵守納斯達克持續上市要求,具體來說,公司公開持股市值和上市證券市值均低於最低閾值。 Conduit有180天恢復符合條件。 此外,董事未公開出售大量公司股份,並發現大股東的股份被第三方質押。 董事會已成立特別委員會和交易審查委員會調查和解決這些問題。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息